Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2001

View Archived Issues

Phase II trial initiated for BLP25 vaccine for prostate cancer

Trinity Biotech launches new one-step malaria test

Replagal therapy for Fabry's disease approved in New Zealand and Iceland

Phase I/II trial results for CG-7870 discussed at ECCO 11

Micafungin undergoing regulatory review in Japan

Antiemetic agent developed in Japan to be submitted for approval within the year

Clinical testing of NIK-333 commences

Compound for SIADH designated an orphan drug in Japan

Vasopeptidase inhibitors from Bioprojet to be developed, marketed by Lilly

U.S. clinical trials of new polyamine drug SL-11047 will now begin

Induction of therapeutic angiogenesis by molgramostim in patients with CAD

Demegen expands pipeline for treatment of cystic fibrosis through CFF grant

Zindaclin receives approval in U.K. as acne treatment

ALT-711 enters a second systolic hypertension trial

Minimal toxicity seen in phase I studies of new camptothecin conjugate

Novo Nordisk makes further investment in Aradigm's AERx iDMS program

Combination therapy with PKC-412, 5-FU and leucovorin evaluated in phase I trial

Cell Therapeutics and Chugai establish agreement to develop cancer product

Biomira to commence interim analysis of Theratope vaccine in the third quarter of 2002

Geron grants Dendreon nonexclusive license for telomerase technology

Genzyme receives FDA complete response letter for Fabrazyme

Nonopioid analgesic effects reported for nitecapone and other COMT inhibitors

New substituted thiazole derivatives synthesized at Janssen and use of the same

Patent coverage obtained for new myt1 kinase inhibitors

Series of selective COX-2 inhibitors useful for wide range of disorders according to recent patent

Bayer presents new compounds stimulating erythropoiesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...